INTRODUCTION
Prior studies unambiguously demonstrate that inherited variation is a determinant of gene expression (Cheung et al., 2003; Montgomery et al., 2010; Pickrell et al., 2010; Schadt et al., 2003; Stranger et al., 2005) . Polymorphisms associated with messenger RNA (mRNA) levels are typically referred to as expression quantitative trait loci (eQTLs). eQTL studies have shed light on the genetic architecture of gene expression. eQTLs have also provided key insights into genes and pathways underlying the associations by providing an intermediate phenotype between non-protein-coding genetic variants and complex traits (Chen et al., 2008; Cookson et al., 2009; Emilsson et al., 2008; Grisanzio et al., 2012; Musunuru et al., 2010; Pomerantz et al., 2009) . In fact, trait-associated loci are enriched for eQTLs (Nicolae et al., 2010) . Most of our knowledge, however, is based on data derived from cell lines and normal tissues (Dimas et al., 2009; Myers et al., 2007; Nica et al., 2010) . By contrast, cancer studies typically generate more expression data on tumors than in normal tissues.
Mapping eQTL-target gene associations in tumor tissue presents additional analytical challenges. Tumors acquire frequent genetic and epigenetic alterations, which can substantially affect gene expression. For example, somatic copy-number changes and DNA methylation status are known to strongly influence transcript abundance in tumors (Curtis et al., 2012; Portela and Esteller, 2010) . Consequently, the effect of these somatic alterations may obscure the association between germline genetic polymorphisms and gene expression. The creation of publicly available large-scale data sets, such as The Cancer Genome Atlas (TCGA) and Encyclopedia of DNA Elements (ENCODE), provide comprehensive catalogs of multiple data types performed on the same set of samples. In this study, we use these resources to develop a general method that models transcript levels as having inputs from germline and somatic factors.
eQTL-based strategies provide a straightforward method for linking non-protein-coding risk alleles discovered through genome-wide association studies (GWAS). Understanding the genes and pathways underlying common risk alleles remains a formidable challenge because the majority of trait-associated polymorphisms are outside of known protein-coding regions (Hindorff et al., 2009 ). Many of these loci are thought to be involved in transcriptional regulation (Freedman et al., 2011; Nicolae et al., 2010) . Therefore, eQTL-based approaches are well suited to identifying candidate genes acting through these loci. We apply our method to known breast cancer risk alleles discovered through GWAS to link the risk variants with their target genes.
RESULTS
The results are presented in two main sections. First, a general approach is described to identify cis-acting eQTL-target gene pairs in tumor genomes while adjusting for other factors that can also influence transcript abundance. Using this method, we conducted a study to identify determinants of transcript variation in the TCGA breast cancer samples.
Next, to gain biologic insights into known breast cancer risk polymorphisms, we hypothesized that the breast cancer risk alleles previously discovered through GWAS are eQTLs. We performed separate cis-and trans-based eQTL analyses for 15 previously identified risk loci in the TCGA breast cancer data sets.
Breast Cancer Data Set
We selected 407 patients with both tumor samples and matched normal blood samples from the TCGA breast cancer data set. For each of these samples, we obtained the germline genotypes from the normal blood sample and the somatic copy number, methylation, and mRNA gene expression measures from the matched tumor sample (Table S1 , available online). Ancestry was inferred using genotype data resulting in 273 cases of European ancestry. In the analyses below, 171 estrogen receptor (ER)-positive cases and 48 ER-negative cases (as determined by ESR1 expression levels) were used (Experimental Procedures).
eQTL Analysis of ER-Positive Breast Cancer For a given gene i and a SNP locus j, we consider three factors of transcript abundance (T): the germline genotypes as the genetic determinants (G), the somatic copy number alterations (Sc), and the CpG methylation levels in the promoter region (M). We first used multivariate linear regression (Equation 1) to compute the residual expression ε i of Sc i and M i :
Then we regress on the residual expression ε i to the germline genotypes G i where u i is the random error.
Thus, the effects of the genetic determinants, the somatic copynumber changes, and the methylation levels on the transcript abundance are estimated separately. Using this model, we evaluated the association between the germline genotypes of 816,362 SNP loci and genes within 1 Mb on either side of each SNP locus. In order to further control the false-positive rate, we excluded 396 genes with low expression levels (less than 10% present calls-an Affymetrix quality metric that determines whether a given transcript is expressed), 85 genes with probes having a known sequence polymorphism, and the highly polymorphic human leukocyte antigen (HLA) region. A Q-Q plot of the raw p-values corresponding to the cis-associations tested before and after adjusting for somatic factors suggests systematic bias in the unadjusted data (l = 1.29), which is eliminated after the adjustment (l = 0.94$1.01, Figure S1 ).
Significant associations were determined by applying a falsediscovery rate (FDR) threshold of less than 0.1. As a result, from 8,107,200 unique SNP gene pairs we identified 6,046 associations with raw p values below 7.50 3 10 À5 . These associations mapped to a total of 6,145 SNP loci and 1,359 unique target genes (Table S2 ). The fraction of variation of the expression levels explained by the associated cis-acting SNP loci (R 2 )
ranged from 18.5% to 73.2%. Of the target genes, 689 (50.7%) are regulated by a single cisacting SNP locus ( Figure S2A) ; the rest are regulated by multiple loci (2-83). After adjusting correlated loci by stepwise feature selection (Experimental Procedures), 664 genes (48.9%) are explained by multiple SNP loci (median = 4), suggesting the existence of multiple independent eQTLs. Of the 5,893 cis-acting eQTL loci, 5,669 cis-acting eQTL loci are associated with one target gene, suggesting that the associations are highly locus specific ( Figure S2B ). cis-associations typically occur within the two nearest transcripts (39.8%) of the eQTL; an additional 18.9% occur between the three to five nearest transcripts ( Figure S2C ).
Determinants of Transcript Levels
Transcript levels of 8,568 genes (54.5% of the total genes tested) are significantly affected by the somatic copy-number changes in the corresponding coding regions (FDR < 0.1). Among the 1,359 target genes of the cis-acting SNP loci, 880 (64.8%) are also significantly associated with somatic copy number. We also identified 2,529 transcripts (16.1% of the total genes tested) that are affected by the methylation of CpG islands in the promoter region (FDR < 0.1). Among these genes, 210 are also target genes of eQTLs (15.5%, Figure 1A ). Of the 15,732 genes tested, the cis-acting SNP loci account for 1.2% of the total variance of the expression. Somatic copy-number alterations account for 7.3% and methylation status accounts for 3.3% of variation in gene expression ( Figure 1B ).
eQTL Analysis of ER-Negative Breast Cancer
To compare the genetic determinants of gene expression in different subtypes of breast cancer, we performed a cis-eQTL analysis for 48 ER-negative breast cancer samples. Based on the model described above, we identified 380 significant cisassociations (FDR < 0.1), mapping to 380 SNP loci and 179 target genes (Table S3) . Notably, only 43 target genes (24.0%) from ER-positive tumors are represented in the significant associations in ER-negative tumors.
eQTL Analysis of Breast Cancer Risk Loci cis-Analysis We focused on 15 breast cancer loci previously reported by genome-wide association studies (p < 5 3 10
À8
, Table S4 ) (Hindorff et al., 2012) . We identified three significant cis-associations mapping to risk loci at 2q35 (IGFBP5), 5q11 (C5orf35), and 16q12 (TOX3) (FDR < 0.1, Table S5 ). trans Analysis We next hypothesized that the 15 GWAS-identified risk loci are cis-acting eQTLs of transcription factors (TFs), which in turn influence multiple downstream targets. In such cases, the activity level of a given TF may be more accurately reflected in the expression levels of its target genes (Essaghir et al., 2010; Wolfer et al., 2010) . It is then possible to examine the set of eQTL-associated genes and then work ''backwards'' to evaluate whether a TF binding motif is enriched in the target genes (Figure 2) . Thus, each risk locus will be associated with a set of target genes. For each set of target genes, the putative enhancer regions, as defined by ENCODE-generated DNaseI hypersensitivity (DHS) data from the MCF-7 cell line (a breast cancer cell line), were analyzed for TF DNA binding motif enrichment (Experimental Procedures) . This analysis revealed three risk loci for which the target genes are significantly enriched for three particular TF motifs (6q25/ESR1; 9q31/KLF4, and 8q24/MYC) (Table 1) . Moreover, as mandated by our analysis, the particular TF whose motif is overrepresented in the target genes is physically located near the risk locus. Of note, 6 of the 15 risk loci have a TF located nearby, but the TF motif is not enriched in the target genes (Table S6) .
The ESR1 enrichment is of particular significance as ESR1 encodes the ER, the defining TF of this class of breast cancer. To further evaluate the ER binding sites as defined by in vivo occupancy, we used the ER cistrome previously defined by chromatin immunoprecipitation in MCF-7 cells (Carroll et al., 2006) . The regions within the 6q24 gene set that are computationally predicted to bind ER by the presence of an ER DNA binding motif are significantly enriched for in vivo ER binding sites defined by chromatin immunoprecipitation (p < 1 3 10 À6 ).
Of note, the ESR1, KLF4, and MYC RNA expression levels were not significantly associated with genotypic status. Since TF expression levels tend to be under tight regulatory control and are present at low cellular concentrations (Vaquerizas et al., 2009) , TFs may be difficult to detect using an eQTL-based methodology. S1 and S2 and Tables S1,  S2 , S3, and S5.
A complementary method of identifying cis-regulated genes is allelic imbalance (AI). AI for a given gene can be measured when an individual is heterozygous for a transcribed polymorphism. Significant deviations from a 1:1 ratio in the maternal: paternal RNA levels indicate genetic and/or epigenetic cis-influences on a gene (Babak et al., 2010; Campino et al., 2008; Ge et al., 2009; Heap et al., 2010) . Recently released TCGA RNA-sequencing data enable evaluation of AI in tumor samples (Experimental Procedures). The expectation is that individuals who are heterozygous for the functional regulatory polymorphism (or any variant in linkage disequilibrium with it) will display AI in the target gene, while homozygous individuals will demonstrate less AI (Forton et al., 2007; Lefebvre et al., 2012) (Figure S3 ).
Breast cancer TCGA RNA-seq data from 177 individuals were evaluated for the relationship between genotypic status at the risk alleles and AI (Table S7) . After removing cases with somatic copy-number alterations, our results demonstrated that the 6q25 and 8q24 risk loci are significantly associated with allelic specific expression of ESR1 and MYC, respectively (p = 0.017 for rs2046210/ESR1 and p = 0.035 for rs418269/MYC; Figures 3A and 3B). As expected, the AI is greatest in individuals heterozygous for the risk variant. No significant association was observed for KLF4; however, the power was limited due to fewer informative variants in the transcribed region ( Figure 3C ).
To validate the computational results, we sought experimental evidence by chromosome conformation capture (3C) to evaluate physical interactions between the risk loci and the promoters of the TFs. Since the MYC locus has already been shown to interact with the 8q24 risk locus (Ahmadiyeh et al., 2010; Wright et al., 2010; Yochum et al., 2010) , we tested for interactions between the ESR1 and KLF4 promoters and the 6q25 and 9q31 risk regions, respectively (Experimental Procedures). In estradiolstimulated MCF-7 cells, we observed sequence-verified interaction products for 6q25 and 9q31 at distances of 189 kb and 644 kb, respectively (Figure 4 ).
DISCUSSION
Most of our knowledge of the genetics of gene expression has been derived through studies conducted in cell lines and normal primary tissues. Understanding the germline contribution to gene expression levels in tumors is confounded by the acquisition of complex somatic and epigenetic alterations, as well as a dearth of data sets measuring this information on a common set of samples. Although eQTL studies using tumors have been reported, the effects of somatic genetic and epigenetic factors have not been addressed (Grisanzio et al., 2012; Kristensen et al., 2006; Pomerantz et al., 2010) . Our method provides a practical solution to account for the multiple factors that determine gene expression levels. Moreover, the method is easily expandable to accommodate other factors, such as somatically acquired single-nucleotide variants, that may influence gene expression and can be applied to the growing availability of genome-wide tumor data sets.
The overlap of eQTL-target genes between ER-positive and ER-negative samples is approximately 25%. Although the literature continues to emerge on this topic, this degree of eQTL sharing is what is typically observed between different tissue types (Dimas et al., 2009; Nica et al., 2010) . The data are consistent with these tumors arising from different cell types.
The breast cancer risk SNP analysis provides a working model of the biology for non-protein-coding risk alleles. Both cis-based and trans-based analyses were performed. In the cis-analysis, we observed three transcripts associated with three risk loci at an FDR < 0.1 (2q35/IGFBP5, 5q11/C5orf35, and 16q12/TOX3). Interestingly, the association with TOX3 (in the same direction) has been previously observed, further demonstrating the utility of publicly available data (Riaz et al., 2012) . IGFBP5 is a strong candidate gene for mediating the effect of the 2q35 risk locus. In breast cancer cell lines, IGFBP5 overexpression affected cell-cycle regulation and apoptosis (Butt et al., 2003) . In transgenic mice, IGFBP5 expression interferes with mammary epithelial development (Tonner et al., 2002) . IGFBP5 expression levels have also been shown to be a marker of poor outcome in patients with breast cancer (Becker et al., 2012) . Our analysis does not support the previously described association between the 10q risk locus and FGFR2 levels (p = 0.537). Prior studies have yielded inconsistent results with three studies demonstrating an association and two that have not (Huijts et al., 2011; Martin et al., 2011; Meyer et al., 2008; Riaz et al., 2012; Sun et al., 2010) . Variability between the studies may be due to different sample sizes, different tissue types (normal, tumor), and/or measurement of different isoforms. The largest study was performed on 1,401 breast tumor samples and the results showed no association. eQTL studies performed in different cell types and across the full spectrum of expressed isoforms will help to further clarify these observations.
The trans analysis for the breast cancer risk loci supports the assertion that some risk alleles act through TFs that, in turn, influence their target genes. The data demonstrate that target genes of a TF can be used as a surrogate readout for TF activity as has been shown in a recent study (Small et al., 2011) . For example, 8q24-associated target genes are enriched for the MYC motif, providing an additional layer of support that MYC is a common upstream TF. In addition to MYC, we discovered that the 6q25 and 9q31 risk loci act through the ESR1 and KLF4 TFs. Since the TFs themselves were not associated with genotypic status using an eQTL-based method, we turned to measuring allelic expression of the TFs.
AI is an intuitively advantageous method of detecting cis-regulatory effects. Theoretically, correlating AI with genotypic status should be more sensitive than eQTL-based analyses because the comparison is made within an individual (using the other chromosome as a control), thereby removing sources of environmental noise (Fogarty et al., 2010) . By applying AI to the TFs and correlating the AI with genotypic status at the risk loci, we demonstrated that MYC and ESR1 are significantly imbalanced in individuals that are heterozygous for the risk locus. A prior report also demonstrated allelic imbalance in MYC expression levels in a colon cancer cell line heterozygous for the 8q24 colon cancer risk allele (Wright et al., 2010) . KLF4 did not reveal allelic imbalance, most likely due to the low prevalence of informative markers in the KLF4 transcript. The AI method requires appreciable numbers of heterozygous (informative) sites in expressed transcripts. Nevertheless, KLF4 is a strong candidate gene. In prior studies, knockdown of KLF4 in MCF-7 cells affected proliferation, migration, and invasion (Akaogi et al., 2009; Yu et al., 2011) . In addition, KLF4 has been shown to play a potent oncogenic role in mammary tumorigenesis by maintaining stem cell-like features (Yu et al., 2011) . In agreement with the importance of KLF4 in driving stem cell features is the seminal observation that KLF4 is one of four TFs required for generating induced pluripotent stem cells (Takahashi et al., 2007) .
eQTL-based analyses represent one strategy for detecting how risk alleles exert their effects on gene expression. Negative results can be attributed to biologic and technical reasons. For example, a variant may influence expression only at a certain developmental time point or in a non-cell-autonomous fashion. In addition, most of the eQTL analyses are based on measures of steady-state expression levels; however, a variant could be influencing the non-steady-state aspect of expression, such as rate of transcription. A negative eQTL result may also arise from technical limitations, which can occur due to a lack of power to detect a subtle, but biologically important, change in transcript levels. Testing associations with other transcribed elements, such as transcript isoforms as well as small and long noncoding RNAs, will also be informative. Moreover, it will be interesting to compare eQTL-target gene results in tumors with results derived from normal tissues. The ability to systematically test many of these hypotheses in the near future will be possible given the proliferation of deeply characterized data sets (e.g., GTEx [http://commonfund.nih.gov/GTEx/] and MuTHER [http:// www.muther.ac.uk/]).
While the TCGA was primarily envisioned as a somatically oriented database, we utilized both germline and somatic information to reveal how the data can be used to shed light on risk alleles discovered through GWAS. Our analyses highlight the power and promise of using publicly available data sets to derive biologic insights in unanticipated ways.
EXPERIMENTAL PROCEDURES

Data Sets
The breast cancer data set was downloaded from ''The Cancer Genome Atlas'' data portal (https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp). The germline genotypes are measured from blood-derived DNA samples and the expression profile, the somatic copy number, and methylation are measured and inferred from matched tumor samples (Table S1 ).
Verification of Ancestry
We selected 250,160 SNP loci with allele frequencies above 0.05 from the SNP profiles of 407 breast cancer samples (the subjects) and 415 HapMap cell lines (the controls). Then we combined the profiles of the 259,001 SNPs from the breast cancer samples and the HapMap cell lines. The combined SNP profiles were run on the EIGENSTRAT program and the top two principal components (PC1 and PC2) were retrieved. From the 273 samples that coclustered with HapMap CEU controls, we further selected 171 cases with high ESR1 expression levels (above 1) and 48 cases with low ESR1 expression (below 0) with both segmented copy number and methylation measures available.
The Somatic Copy Number and Methylation of Transcripts
To determine the copy-number changes for a given transcript, we retrieved the segmented copy-number scores of the tumor sample and the paired-normal control from the level 3 TCGA data, which were both inferred from the Affymetrix SNP 6.0 platform. Then for each transcript, we calculated the average of the segmented copy-number scores of the genetic interval between the transcription start and end sites as the gene-based somatic copy-number measure ( Figure S4A ).
The CpG methylation measure of each sample was profiled using the HumanMethylation27K array by Illumina, which assays 27,578 CpG sites per sample. These 27,578 sites represent 14,475 consensus-coding sequences across the genome, providing approximately two CpG assays per gene, with increased targeting of cancer-related genes. Then the CpG methylation status was determined by discretization CpG methylation measure with cut-off values of 0.2, 0.4, and 0.6 ( Figure S4B ).
Association Analyses
In the cis-or local eQTL analysis we evaluated the associations between the genotype at a given SNP locus and transcripts located within a 2 Mb interval (1 Mb range up-and downstream). We excluded 90,238 SNP loci with minor allele frequency < 0.05 and 396 genes with low expression levels-absent calls in more than 90% of the samples. The expression profile of each gene was first adjusted for somatic copy-number effects and CpG methylation using a multivariate linear model. The p value corresponds to the regression coefficient based on the residual expression level and the germline genotype.
We performed cis-eQTL analysis between 816,362 SNP loci (22 autosomes and X chromosome) and corresponding mRNA transcripts in ER-positive breast cancer and ER-negative breast cancer, respectively. To control for the false predictions, we excluded genes with absent call in over 90% of the samples and genes of which the probes sets are affected by one or multiple known SNP loci. We also excluded the HLA locus given the high levels of polymorphism in this region. The Benjamini-Hochberg method was used to correct the raw p values and a significant association was based on a threshold of FDR of 0.1.
We assessed 15 previously reported breast cancer risk loci for the regulatory potential in gene expression of breast cancer cells (Table S4) . Any variant that achieved p < 5 3 10 À8 was selected. To adjust for the effects of somatic factors, we performed multivariate linear regression of the tumor gene expression on somatic copy number and methylation and used the scaled residuals as adjusted measures of gene expression. Then, a second regression of the adjusted gene expression on the germline genotypes of each of the 15 risk loci was performed. The significance of the association between a given risk locus and a gene is given by the test p value corresponding to the regression coefficient of the genotype. We called significant associations based on a p value threshold of 0.05. The genes associated with a risk locus at a given significant level are then defined as the target genes of the locus.
Motif Analysis
For each risk locus, we selected the target genes based on significant associations (p < 0.05). Then for each of the target genes, we selected 1-50 kb regions on both sides of the transcription start site as putative enhancer regions. We next retrieved all the sites overlapping the DHS peaks in the ENCODE MCF-7 DNaseI-seq data generated by the Stamatoyannopoulos group (Birney et al., 2007) (http://hgdownload.cse.ucsc.edu/goldenPath/ hg19/encodeDCC/wgEncodeUwDnase/). Thus for each risk locus, we obtained a set of DNA sequences from the putative enhancer regions of the target genes. To control for directional regulatory effects, we considered upregulated and downregulated target genes separately. Then we identified the binding motifs of known TFs from databases embedded in cistrome, including Transfac, JASPAR, UniPROBE (pbm), and hPDI (Liu et al., 2011) , which are significantly overrepresented in these sites (p < 1 3 10 À6 ). We further mandated that the TF whose motif was enriched in the target genes be located within 1 Mb range of the corresponding risk locus. If a transcription factor satisfies these criteria, we considered it as a candidate for empirical 3C validation.
To verify that the ESR1 binding site is enriched in the 476 target genes of 6q25 risk locus, we randomly sampled the entire genome 1 million times. Each time, we picked up 476 genes and counted the occurrence of the ESR1 binding site in the putative enhancer regions (1 kb to 50 kb) according to the ChIP-seq study. Then we compared the number of ESR1 binding sites found in the random gene sets to that of the 476 6q25 target genes to compute a simulated p value for enrichment.
Determination of AI and Correlation with Risk Allele Status
One hundred seventy-seven breast cancer samples with Caucasian ancestry were selected from the TCGA database using EIGENSTRAT. The corresponding RNA-sequencing data sets are available in BAM format from ''Cancer Genomics Hub'' (CGHub) (https://cghub.ucsc.edu/). We marked all the exonic SNP loci (marker SNP, Table S6 ) mapping to the three TF genes (ESR1, MYC, and KLF4) based on National Center for Biotechnology Information dbSNP build 135. Then for each sample j, we retrieved all the RNA-sequencing reads mapped to the marker SNP locus i and counted for the occurrence of reference (A ij ) and alternative (B ij ) alleles.
We excluded all SNP loci with low coverage (less than 153), homozygosity (only one allele present in the mapped reads), and somatic copy-number changes (copy-number measure 1.5-2.5). For each individual and for a given transcribed SNP, we calculated a measure of allelic imbalance m given by Equation 3:
Marker SNP loci with extreme major allele fraction (above 0.8) are excluded as many of these loci are falsely called homozygous by sequencing errors. When multiple SNP loci were found for a gene in sample j, the average allelic imbalance across all of the marker SNP loci was used to represent that gene. For each of the three breast cancer risk loci and corresponding TF, we assessed the association between m ij and the heterozygosity (AB versus AA and BB) using F-test p values ( Figure S3) .
In order to address the reference bias introduced by aligning sequencing reads to the reference genome, we also examined the distribution of the reference allele fraction for all the exonic SNP loci that have been used to determine AI status, which showed no bias toward the reference allele ( Figure S4C ).
3C and PCR
MCF7 cells were purchased from ATCC and grown in estrogen-depleted media for 3 days and treated with 10 nM of 17b-estradiol for 45 min as performed in Shang and Brown (2002) . A 3C library was then prepared as previously described (Pomerantz et al., 2009) . Briefly, after hormone treatment, MCF7 cells were trypsinized, fixed with 1% formaldehyde, and lysed with 3C lysis buffer (10 mM TrisHCl [pH 8], 10 mM NaCl, 0.2% Nonidet P-40). The pelleted cell nuclei were resuspended in restriction butter with SDS (final concentration 0.1%) and incubated for 10 min at 65 C. Then, Triton X-100 (final concentration 1%) and HindIII 160 U per 1 3 106 cells were added and incubated for 24 hr at 37 C on a rotating platform. The digested samples were added to the 3C ligation mix buffer with T4 DNA ligase and incubated for 24 hr at 16 C. The ligated samples were decrosslinked at 65 C with proteinase K overnight and were Phenol/Chloroform extracted, EtOH precipitated, and desalted. Target primers were designed against HindIII-digested fragments within or close to DHS around SNPs in the region of risk loci and anchor primers were designed against the fragments cut by HindIII in the TF promoters (primers available upon request). PCR was performed using Taq polymerase (QIAGEN), 3C library, and the oligonucleotides listed in Table  S3 . PCR conditions were as follows: 5 min at 94 C (20 s at 94 C, 20 s at 57 C, and 30 s at 72 C) 3 42 cycles, and 10 min at 72 C for extension. Seven microliters of PCR samples were loaded on the 1.7% agarose gel. The PCR products were then gel purified and sequenced. Since spurious interactions are typically undetectable beyond 150 kb, the ESR1 and KLF4 ligation fragments represent bona fide interactions. Please see also Figure 3 and Table 1 .
Additional Information
The results published here are in whole or part based upon data generated by The Cancer Genome Atlas Pilot Project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions that constitute the TCGA research network can be found at http://cancergenome.nih.gov. All the data we used for this study were generated and available from TCGA, in which proper patient consent guidelines have been applied. The request for TCGA data access [#11820-4] was approved by the TCGA Data Access Committee.
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